Sartorius Stedim Biotech provides earnings guidance for the full year 2022. The company expects Sales revenue to increase by 14% to 18% with sustained high profitability.
Market Closed -
Other stock markets
|
Pre-market 01:57:14 am | |||
178.8 EUR | -0.69% | 180.2 | +0.81% |
Jun. 03 | SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%) | |
May. 16 | Sartorius sinks again towards year low | DP |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.37% | 18.61B | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+2.92% | 41.61B | |
+19.93% | 31.07B | |
+10.43% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- DIM Stock
- News Sartorius Stedim Biotech
- Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022